Imugene (ASX: IMU) steps up dosage at groundbreaking VAXINIA cancer trial (w/ Leslie Chong)

Small Caps

Small Caps에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Small Caps 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

3M ago 19:18

MP3•에피소드 홈

Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company’s phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA.

The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials,

Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab.

Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase.

Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

Articles:
https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/
https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/

For more information on Imugene:
https://smallcaps.com.au/stocks/asx-imu/

See omnystudio.com/listener for privacy information.

124 에피소드

#Business News #News #Small Caps #Trading #Business